RhD+ Blood Transfusion to Asian-type DEL Recipients

Summary

Red blood cells (RBCs) from Asian-type DEL blood group express very weak RhD antigen and are falsely typed as RhD-negative blood group in routine RhD testing. Until now, Asian-type DEL (D-eluate) patients still be treated as rare RhD-negative patients in the clinic. Previous study from the Asian-type DEL pregnant women with RhD+ fetus showed no occurrence of alloanti-D immunization. This result, however, does not directly be applied for Asian-type DEL patients receiving RhD+ blood transfusions, as lacking of direct evidence regarding the safety and underlying mechanism.

In this study, the patients with Asian-type DEL were identified and received RhD+ blood transfusion, then evaluations of any adverse reactions, especially the active follow-up alloantibody test, were prospectively conducted.

Conditions

• Blood Transfusion
• Rhesus Isoimmunisation Due to Anti-D
• Blood Group Antigen Abnormality

Interventions

OTHER

Blood transfusion

Transfusion with RhD+ blood product rather than rare RhD-negative blood to Asian-type DEL recipients

Sponsors & Collaborators

• Sun Yat-sen University

  collaborator OTHER

• Southern Medical University, China

  collaborator OTHER

• Guangdong Provincial People's Hospital

  collaborator OTHER

• Third Affiliated Hospital, Sun Yat-Sen University

  collaborator OTHER

• Zhujiang Hospital

  collaborator OTHER

• Second Affiliated Hospital of Guangzhou Medical University

  collaborator OTHER

• Guangdong Provincial Hospital of Traditional Chinese Medicine

  collaborator OTHER

• The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine

  collaborator OTHER

• Guangdong Second Provincial General Hospital

  collaborator OTHER

• First Affiliated Hospital, Sun Yat-Sen University

  collaborator OTHER

• Guangdong Provincial Institute of Biological Products And Materia Medica

  collaborator OTHER

• Shenzhen Second People's Hospital

  collaborator OTHER

• Koo Foundation Sun Yat-Sen Cancer Center

  collaborator OTHER

• Guangzhou Blood Center

  lead OTHER_GOV

Principal Investigators

• Yongshui Fu, MD, PhD · Guangzhou Blood Center

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-10-01

Primary Completion

2021-10-09

Completion

2021-11-30

Countries

• China

Study Locations